Oppenheimer Upgrades Compass Pathways (CMPS) to Outperform

Oppenheimer analyst Francois Brisebois upgraded Compass Pathways (NASDAQ: CMPS) from Perform to Outperform with a price target of $15.00.

The analyst comments "We're moving CMPS to Outperform with a $15PT (prev. Not Rated) based on our conviction for COMP360 to lead the revolution of psychedelic medicine for neruopsychiatry. We anticipate COMP360 (psilocybin) to become the first-ever FDA-approved classical psychedelic therapy for treatment-resistant depression (TRD) patients where we see a ~$1.5B peak sales opportunity. CMPS recently outlined an accelerated regulatory pathway with FDA alignment enabling potential launch in 2027. Meanwhile, we see shares as attractive ahead of important readouts from the ongoing Ph3 program in 1Q26. Our KOL diligence supports our optimism considering trial design dynamics and differentiation for COMP360. We expect a first-mover advantage among psychedelics plus commercial tailwinds from Spravato. We view CMPS as financially well-positioned with cash runway beyond key catalysts."

For an analyst ratings summary and ratings history on Compass Pathways click here. For more ratings news on Compass Pathways click here.

Shares of Compass Pathways closed at $6.30 yesterday.

You May Also Be Interested In